(Q37450782)

20 August 2017

1 reference

title

Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications (English)

1 reference

20 August 2017

0 references

Praneet Kumar

1

1 reference

20 August 2017

Gary S Francis

series ordinal

2

1 reference

20 August 2017

W H Wilson Tang

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Nature Reviews Cardiology

20 August 2017

published in

1 reference

20 August 2017

volume

6

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

349-355

1 reference

Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sympathetic activation by sildenafil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Overview of PDEs and their regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Expression, distribution and regulation of phosphodiesterase 5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sildenafil citrate does not affect cardiac contractility in human or dog heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sildenafil citrate therapy for pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Long-term use of sildenafil in the therapeutic management of heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Effect of sildenafil on cardiac performance in patients with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Type 5 phosphodiesterase inhibition in heart failure: the next step

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Phosphodiesterase type 5: expanding roles in cardiovascular regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.32

Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19377497

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2009.32

1 reference

20 August 2017

1 reference